Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

138.26 +0.15 (+0.11%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...

Via MarketMinute

GBK Brand Bar and Meals on Me Host the Official Backstage Lounge at the 40th Annual Rock & Roll Hall of Fame Induction Ceremony Rehearsals

November 10, 2025

November 10, 2025 -- During rehearsals leading up to the Induction Ceremony, GBK welcomed some of the world's biggest musicians from legendary icons to today's top superstars.

Via 24-7 Press Release

Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗

November 09, 2025

Via Stocktwits

What's going on in today's session: S&P500 movers ↗

November 07, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend ↗

November 07, 2025

Gilead's Trodelvy missed a key goal in breast cancer, while Livdelzi showed durable efficacy and safety in long-term liver disease studies.

Via Benzinga

Gilead Provides Update on Phase 3 ASCENT-07 Study

November 07, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression

November 07, 2025

From Gilead Sciences, Inc.

Via Business Wire

Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns

November 06, 2025

The third-quarter 2025 earnings season, largely drawing to a close in early November, has proven to be a dynamic and often surprising period for investors. While a significant majority of S&P 500...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions

November 06, 2025

Gilead Sciences’ third quarter was marked by strong sales growth in its HIV and liver disease portfolios, but the market responded negatively due to ongoing concerns about oncology revenue and broader...

Via StockStory

Topics Earnings

3 Cash-Rich Stocks With High Growth Potential Right Now ↗

November 05, 2025

Via MarketBeat

10 Health Care Stocks Whale Activity In Today's Session ↗

November 05, 2025

Via Benzinga

Gilead Sciences Inc (NASDAQ:GILD) Appears as a Decent Value Stock ↗

November 05, 2025

Gilead Sciences (GILD) appears undervalued with a low P/E ratio, strong profitability, no debt, and a solid dividend, fitting classic value investing principles.

Via Chartmill

Moderna Earnings: What To Look For From MRNA

November 04, 2025

Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Thursday before the bell. Here’s what investors should know.

Via StockStory

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

November 04, 2025

The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...

Via TokenRing AI

Topics Artificial Intelligence

Gilead Sciences to Present at Upcoming Investor Conferences

November 04, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

November 03, 2025

From Gilead Sciences, Inc.

Via Business Wire

Gilead Sciences Inc (NASDAQ:GILD): A Dividend Stock with a Secure Payout and Strong Fundamentals ↗

November 03, 2025

Gilead Sciences (GILD) offers a 2.64% dividend yield with a very low payout ratio, strong profitability, and a debt-free balance sheet, making it a compelling dividend stock.

Via Chartmill

Amgen Earnings: What To Look For From AMGN

November 02, 2025

Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings this Tuesday after market close. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings

November 01, 2025

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results this Monday after the bell. Here’s what to expect.

Via StockStory

Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect

November 01, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know.

Via StockStory

Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout

October 31, 2025

Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant...

Via MarketMinute

Topics Intellectual Property

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026 ↗

October 31, 2025

Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for 2026.

Via Benzinga

Topics Earnings

Gilead GILD Q3 2025 Earnings Call Transcript ↗

October 31, 2025

Gilead GILD Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday? ↗

October 31, 2025

Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive.

Via Benzinga

GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds

October 31, 2025

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 3% year on year to $7.77 billion. On the other hand, the...

Via StockStory

Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)

October 31, 2025

From Gilead Sciences, Inc.

Via Business Wire

Meta Meltdown Sends Nasdaq Tumbling as Apple Shines After Hours ↗

October 31, 2025

Wall Street slipped on Thursday as disappointing results from Meta and cautious tones from the Fed weighed on sentiment. But after the closing bell, Apple’s record-breaking numbers helped restore a bit...

Via Chartmill

Topics Economy

Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares? ↗

October 31, 2025

Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?

Via The Motley Fool

Topics Regulatory Compliance

Gilead Sciences Inc (NASDAQ:GILD) Reports Mixed Q3 2025 Results with Strong Earnings Beat and Cautious Revenue Outlook ↗

October 30, 2025

Gilead Sciences Q3 2025 earnings beat EPS estimates with $2.47, but revenue outlook is cautious. HIV drug Biktarvy drives growth, while Veklury sales decline.

Via Chartmill

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

72 73 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.